Longevity & Cellular
SS-31 (Elamipretide)
Also published as Elamipretide, MTP-131, Bendavia, SS-31
A four residue peptide with an alternating aromatic cationic structure that concentrates in the inner mitochondrial membrane, where it associates with cardiolipin. It is by a distance the most clinically advanced compound in this catalogue.
Where it came from
Developed from the Szeto-Schiller peptide series at Weill Cornell, then taken into clinical development by Stealth BioTherapeutics.
What the literature examines
- Cardiolipin binding and cristae architecture in the inner mitochondrial membrane
- Ischaemia reperfusion injury models
- Primary mitochondrial myopathy, in registered human trials
- Barth syndrome, in registered human trials
- Geographic atrophy and dry age related macular degeneration
State of the evidence
Multiple registered Phase 1 to Phase 3 trials with published results, which is exceptional for anything in the research peptide trade.
What a buyer should know
Advanced clinical development is not the same as approval, and several of its trials did not meet their primary endpoints. The fact that a compound has real trial data cuts both ways, because the failures are on the record too.
Handling and stability
Lyophilised, water soluble, hold cold once reconstituted.
Sequence
D-Arg-Dmt-Lys-Phe-NH2
Read it yourself
We do not publish a curated citation list, because a hand picked list of papers is a sales tool. These links run a live query against the public databases, so you see everything, including the results that do not suit us.
Supplied for laboratory research use only. Nothing on this page is a dose, a protocol or a claim of effect in humans, and nothing here is medical advice. Read our research use policy.